




Increase the potency of your mRNA with CleanCap® M6 analog

Gain 30%+ higher protein expression with our best cap analog yet

CleanCap® Reagent M6

- CleanCap Reagent M6 [CleanCap m6AG (3' OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base modified Cap 1
- Using the same 5' AG initiation sequence as CleanCap AG and CleanCap AG (3'OMe), the CleanCap M6 analog has the addition of a methyl group on position 6 of the first adenosine (m6A) which may further increase protein expression. It has been hypothesized the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)
- CleanCap M6 can be used in conjunction with wildtype bases or TriLink's catalog of modified NTPs, such as N1-Methylpseudouridine-5'-Triphosphate (N-1081), Pseudouridine-5'-Triphosphate (N-1019), and 5-Methoxyuridine-5'-Triphosphate (N-1093)



CleanCap® Reagent M6

For co-transcriptional capping of mRNA, m7(3'OMeG)(5')ppp(5')
m6(2'OMeA)pG


The #1 capping strategy for mRNA translation

CleanCap® M6 analog increases protein expression by 30%+

From the first CleanCap analog launched in 2017, TriLink has been continuing to improve on its revolutionary capping technology. With the introduction of the CleanCap M6 technology, we have combined the modification of 3'OMe on the m7-Guanosine and the additional methyl modification on the +1 Adenosine, to drive improved mRNA potency with the highest protein expression of any CleanCap analog yet.

CleanCap M6 outperforms previous analogs


In internal comparison studies, our newest cap analog, CleanCap M6, promoted higher protein translation (FLuc) than observed with other CleanCap analogs, driving a potential increase in the potency of your mRNA drug substance.



Performance of FLuc mRNA in an LNP-formulated, tail vein delivered mouse model. 1 mg/kg dose per group. Luciferase activity, as photons per second, is measured after luciferin injection. The difference between groups is cap analog structure. All other variables are controlled.

More potent mRNA than enzymatically capped constructs

When compared to enzymatic capping strategies, the CleanCap M6 analog demonstrated significantly higher protein translation (FLuc), resulting in higher manufacturing yields.



CleanCap M6 analog is available in a variety of pack sizes to try in your experiments today.

Learn more and order online at trilinkbiotech.com/cleancap-reagent-m6

SKU	Unit Size
N-7453-1	1 µmole
N-7453-5	5 µmole
N-7453-10	10 µmole
N-7453-100	100 µmole

Contact us at **800.863.6801** or sales@trilinkbiotech.com to speak with an expert to help identify the best CleanCap® technology for your application.

License is required for commercial use of CleanCap® and CleanCap® products.

For license restrictions and patent(s) information, refer to <https://www.trilinkbiotech.com/legal-notices>

©2023 TriLink BioTechnologies. All rights reserved.

v.05042023